TORRENT DO BRASIL LTDA — Gliclazide Importer Profile
Pharmaceutical Importer · #3 buyer for Gliclazide · $6.9M import value · 284 shipments · BRAZIL · DGFT Verified
TORRENT DO BRASIL LTDA is the #3 importer of Gliclazide from India with $6.9M in import value and 284 verified shipments. TORRENT DO BRASIL LTDA holds a 2.2% market share in Gliclazide imports based in BRAZIL. The company sources from 1 verified supplier across 84 formulations shipped to 1 country. Overall, TORRENT DO BRASIL LTDA imports 6 pharmaceutical products worth $29.0M across 4 therapeutic categories.
TORRENT DO BRASIL LTDA — Gliclazide Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Gliclazide to TORRENT DO BRASIL LTDA?
Verified from 284 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| TORRENT PHARMACEUTICALS LIMITED | $6.9M | 284 | 100.0% |
TORRENT DO BRASIL LTDA sources Gliclazide from 1 verified Indian supplier based on 284 customs records. The primary supplier is TORRENT PHARMACEUTICALS LIMITED accounting for 100.0% of imports.
How Does TORRENT DO BRASIL LTDA Compare to Nearest Gliclazide Importers?
Buyers ranked immediately above and below #3 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | TORRENT DO BRASIL LTDA ★ | BRAZIL | $6.5M | 226 | $29.0K |
| 7 | MEDREICH PLC | UNITED KINGDOM | $3.1M | 68 | $45.7K |
| 8 | M/S. RANBAXY FARMACEUTICA LTDA : | BRAZIL | $2.4M | 48 | $50.0K |
TORRENT DO BRASIL LTDA ranks #3 among 643 Gliclazide importers from India. Average shipment value of $29.0K compared to the market average of $40.7K. The closest competitors by value are MEDREICH PLC and M/S. RANBAXY FARMACEUTICA LTDA :.
Where Does TORRENT DO BRASIL LTDA Import Gliclazide To?
Destination countries from 284 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $6.9M | 284 | 100.0% |
TORRENT DO BRASIL LTDA imports Gliclazide to 1 country. The primary destination is BRAZIL receiving 100.0% of shipments worth $6.9M.
What Gliclazide Formulations Does TORRENT DO BRASIL LTDA Import?
| Formulation | Value | Shipments |
|---|---|---|
| AZUKON MR TABLET ( GLICLAZIDE MODIFIED R | $1.0M | 29 |
| AZUKON MR TABLET (GLICLAZIDE MODIFIED RE | $305.3K | 10 |
| AZUKON MR TABLET GLICLAZIDE 30MG MODIFIED RELEASE TABLETS NOS SIZE 10X10 TABLETS | $300.0K | 6 |
| AZUKON MR TABLET ( GLICLAZIDE MODIFIED RELEASE 30MG ) NOS SIZE 3X10 TABLETS | $260.3K | 6 |
| GLICLAZIDE MR 30MG TABLETS ( GLICLAZIDE | $241.6K | 12 |
| AZUKON MR TABLET GLICLAZIDE MODIFIED R | $240.8K | 7 |
| GLICLAZIDE MR 30MG TABLETS GLICLAZIDEMODIFIED RELEASE 30 MG NOS SIZE 3 X 10TABLETS | $212.4K | 11 |
| GLICLAZIDE MR 30mg TABLETS ( GLICLAZIDE | $189.5K | 9 |
| GLICLAZIDE MR 30MG TABLETS (GLICLAZIDE M | $165.7K | 11 |
| AZUKON MR TABLET ( GLICLAZIDE MODIFIED RELEASE TABLETS 30 MG ) NOS SIZE 6X10 TABLETS | $160.5K | 8 |
TORRENT DO BRASIL LTDA imports 84 distinct Gliclazide formulations from India. The top formulation is AZUKON MR TABLET ( GLICLAZIDE MODIFIED R with 29 shipments worth $1.0M.
Regulatory Requirements: Importing Gliclazide into Brazil
What TORRENT DO BRASIL LTDA and other importers must comply with to import Gliclazide from India
Regulatory Authority
Brazilian Health Regulatory Agency (ANVISA)
Approval Process for Generic Gliclazide
Generic drug registration under RDC 200/2017. Requires pharmaceutical equivalence and bioequivalence studies. ANVISA GMP inspection of overseas facilities mandatory.
Typical timeline: 12–24 months
GMP Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Import Licence & Documentation
Import Authorization (LI) via SISCOMEX; Sanitary Import Permit from ANVISA
Labeling & Packaging
Portuguese language labeling mandatory; ANVISA registration number
Note: ANVISA maintains an active inspection program for Indian pharma facilities. Inspection backlog can extend timelines significantly.
Regulatory information is provided for general reference based on publicly available ANVISA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with ANVISA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Gliclazide from India and How Much Does TORRENT DO BRASIL LTDA Import?
India exported $26.2M worth of Gliclazide through 3,830 shipments from 238 suppliers to 109 countries, serving 643 buyers globally. TORRENT DO BRASIL LTDA imports $6.9M of this total, accounting for 2.2% of India's Gliclazide exports with 284 shipments from BRAZIL. This is verified from 284 customs shipment records covering 84 distinct formulations.
What Is the Average Order Value for TORRENT DO BRASIL LTDA's Gliclazide Imports?
TORRENT DO BRASIL LTDA's average Gliclazide order value is $24.4K per consignment, based on 284 shipments totaling $6.9M. TORRENT DO BRASIL LTDA is based in BRAZIL and ranks #3 among all Gliclazide importers from India by value. The company sources from 1 verified supplier in India.
Who Supplies Gliclazide to TORRENT DO BRASIL LTDA?
TORRENT DO BRASIL LTDA sources Gliclazide from 1 verified Indian supplier: TORRENT PHARMACEUTICALS LIMITED ($6.9M, 100.0%). This is based on 284 customs records.
How Does TORRENT DO BRASIL LTDA Compare to Other Gliclazide Importers?
TORRENT DO BRASIL LTDA ranks #3 among 643 Gliclazide importers from India with a 2.2% market share. The top 3 importers are TORRENT DO BRASIL LTDA ($6.5M), MEDREICH PLC ($3.1M), M/S. RANBAXY FARMACEUTICA LTDA : ($2.4M). TORRENT DO BRASIL LTDA processed 284 shipments from BRAZIL.
About TORRENT DO BRASIL LTDA
TORRENT DO BRASIL LTDA imports 6 products worth $29.0M. Beyond Gliclazide, top products include Rosuvastatin, Calcium, Bisoprolol, Sertraline, Rivaroxaban. View the complete TORRENT DO BRASIL LTDA profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Gliclazide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Gliclazide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: TORRENT DO BRASIL LTDA matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as TORRENT DO BRASIL LTDA's capped import value divided by total capped export value for Gliclazide across all Indian exporters.
- 5.Verified Records: This page is backed by 284 individual customs records matching TORRENT DO BRASIL LTDA importing Gliclazide, covering 84 formulations from 1 verified supplier.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 109+ countries, 643+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Gliclazide Import Data for TORRENT DO BRASIL LTDA
Access order-level details, pricing data, supplier connections, and competitive analysis for TORRENT DO BRASIL LTDA's Gliclazide imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
TORRENT DO BRASIL LTDA
Full Company Profile →
6 products · $29.0M total trade · 4 categories
TORRENT DO BRASIL LTDA × Gliclazide
Verified from customs records
Company Overview
Top Products by TORRENT DO BRASIL LTDA
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for TORRENT DO BRASIL LTDA.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Gliclazide. For current order-level data, contact TransData Nexus.